Furthermore, a pro-fibrotic effect of p300 signaling was demonstrated in LSEC by secretion of monocyte chemoattractant CCL2, which requires the formation of a p300/NFκB/BRD4 activator complex to promote acetylation at the CCL2 enhancer and promoter regions and, thus, may become an interesting target for treatment of portal hypertension and liver fibrosis [130]. This evidence concerns the gene EP300 and portal hypertension.